PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18297287-0	2008	Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell.	gemcitabine	53-64	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	96-101	
18297287-7	2008	Moreover, knockdown of Mcl-1 significantly increased the chemosensitivity to Gemcitabine in pancreatic carcinoma cells.	gemcitabine	77-88	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	23-28	
21566062-4	2011	Importantly, in ABT-737-resistant cancer cells, the interaction between USP9X and Mcl-1, which was increased by ABT-737 treatment, could be disrupted by gemcitabine, thus resulting in enhanced ubiquitination and the subsequent degradation of Mcl-1 and ultimately in the synergism of these two drugs.	gemcitabine	153-164	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	82-87	
18497956-5	2008	A combined Mcl-1 antisense oligonucleotide treatment with paclitaxel, cetuximab and gemcitabine led to a significant reduction in the viable cells.	gemcitabine	84-95	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	11-16	
12138244-7	2002	RNase protection assay showed a negative correlation between bcl-x(L) and mcl-1 mRNA expression levels and the sensitivity to 5-FU and gemcitabine after 5-FU and gemcitabine treatment.	gemcitabine	135-146	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	74-79	
12138244-7	2002	RNase protection assay showed a negative correlation between bcl-x(L) and mcl-1 mRNA expression levels and the sensitivity to 5-FU and gemcitabine after 5-FU and gemcitabine treatment.	gemcitabine	162-173	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	74-79	
12138244-10	2002	The bax/bcl-2 ratio is predictive of chemotherapy sensitivity, whereas bcl-x(L) and mcl-1 mRNA levels following repeated exposure to 5-FU or gemcitabine are associated with resistance to these drugs.	gemcitabine	141-152	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	84-89	
34667112-11	2022	Their synergistic antitumor activity is attributable to DT2216-induced degradation of BCL-XL and concomitant suppression of MCL-1 by GEM.	gemcitabine	133-136	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	124-129	
29138856-12	2018	GEM significantly inhibits the growth and promotes apoptosis of the Eca-109 cells, due to the alterations in the expression levels of the differential proteins, including ASC, Mcl-1 and Bax-alpha.	gemcitabine	0-3	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	176-181	
25885284-9	2015	Cisplatin- and gemcitabine-resistant bladder cancer cells exhibit enhanced basal and drug-induced autophagosome formation and lysosomal activity which is accompanied by an attenuated apoptotic cell death after treatment with both (-)-gossypol and ABT-737, a Bcl-2 inhibitor which spares Mcl-1, in comparison to parental cells.	gemcitabine	15-26	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	287-292	
16469407-10	2006	Selective knockdown of Mcl-1 by siRNA increased gemcitabine-induced cytotoxicity.	gemcitabine	48-59	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	23-28	
34156978-6	2021	We further revealed that leptin can inhibit gemcitabine-induced GBC cell death through myeloid cell leukemia 1 (MCL1) activation.	gemcitabine	44-55	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	87-110	
34156978-6	2021	We further revealed that leptin can inhibit gemcitabine-induced GBC cell death through myeloid cell leukemia 1 (MCL1) activation.	gemcitabine	44-55	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	112-116	
34354046-0	2021	Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.	gemcitabine	0-11	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	167-172	
30320607-7	2019	Moreover, ABT-199 exerted an antagonistic action towards Bcl-2 and Bcl-xL, but to a certain extent moderately increased Mcl-1 level that could be compromised by gemcitabine.	gemcitabine	161-172	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	120-125	
26490978-12	2016	Gemcitabine treatment upregulated the levels of anti-apoptosis proteins (Mcl-2 and Bcl-2) in both scrambled control and maspin-KD cells; however, the fold changes in Mcl-1 and Bcl-2 expression were larger in gemcitabine-treated scrambled control cells than in maspin-KD cells.	gemcitabine	0-11	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	166-171	
21566062-0	2011	Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1.	gemcitabine	34-45	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	127-132	
21566062-4	2011	Importantly, in ABT-737-resistant cancer cells, the interaction between USP9X and Mcl-1, which was increased by ABT-737 treatment, could be disrupted by gemcitabine, thus resulting in enhanced ubiquitination and the subsequent degradation of Mcl-1 and ultimately in the synergism of these two drugs.	gemcitabine	153-164	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	242-247